Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sirius Genomics, a developer of pharmacogenomic tests, has appointed Heiner Dreismann, Chris Fibiger and Patrick Terry to its board of directors.
Subscribe to our email newsletter
Previously, Dr Dreismann served as president and CEO of Roche Molecular Diagnostics, a molecular diagnostics company. Dr Fibiger was previously the vice president and global head of neuroscience at Amgen.
Mr Terry is a social entrepreneur who has founded a series of innovative philanthropic, research, and commercial organizations based on the life sciences, applied technology, and social-network theory.
Brad Popovich, president and CEO of Sirius Genomics, said: “We are extremely pleased to have these individuals join our board. Their global expertise and deep experience in molecular diagnostics, drug development and commercialization will be critical to Sirius as we continue to grow our company. Our board and management team has become an international group containing the highest caliber people in their fields.”